Home » Forest Laboratories Announces Health Canada Approval of Bystolic for the Treatment of Hypertension
Forest Laboratories Announces Health Canada Approval of Bystolic for the Treatment of Hypertension
Forest Laboratories announced that its Canadian subsidiary, Forest Laboratories Canada has received a Notice of Compliance from Health Canada for Bystolic (nebivolol) tablets, a once daily beta blocker for the treatment of hypertension.
BusinessWire
BusinessWire
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May